Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04910568 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Genentech.

Active
Registry status
Phase 1
Development phase
126
Enrollment target
20
Study locations

NCT04910568 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Genentech. The registered enrollment target is 126 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04910568, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Genentech.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
126 participants
Enrollment target
20
Study locations

Study Summary

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Pomalidomide
  • DRUG Tocilizumab
  • DRUG Cevostamab

Study Locations (20)

Other

  • Fakultni Nemocnice Ostrava - Ostrava
  • Rigshospitalet - København Ø
  • Hôpital Saint-Louis - Paris
  • CHU de Poitiers - La Miletrie - Poitiers
  • Rambam Medical Center - Haifa
  • Yamagata University Hospital - Yamagata
  • Pratia Onkologia Katowice - Katowice
  • Uniwersytecki Szpital Kliniczny w Poznaniu - Późna

California

  • City of Hope - Duarte
  • City of Hope - Lennar Foundation Cancer Center - Irvine

Victoria

  • Peter MacCallum Cancer Centre - Melbourne
  • The Alfred Hospital - Melbourne

Ontario

  • Hamilton Health Sciences - Hamilton
  • University Health Network - Toronto

Lombardy

  • Asst Papa Giovanni Xxiii - Bergamo
  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili - Brescia

Colorado

  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center - Denver

Michigan

  • Karmanos Cancer Institute. - Detroit

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2021-07-26
Est. Completion 2029-12-10
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04910568

The ClinicalTrials.gov registry entry for NCT04910568 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT04910568 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Victoria.

Frequently Asked Questions

What is clinical trial NCT04910568 about?

NCT04910568 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma". This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to par...

What is the current status of trial NCT04910568?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2021-07-26. Estimated completion is 2029-12-10.

What conditions does trial NCT04910568 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT04910568?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Tocilizumab (DRUG), Cevostamab (DRUG).

Who is sponsoring clinical trial NCT04910568?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04910568 being conducted?

This trial has 20 study locations across California, Colorado, Michigan, Missouri, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.